Pancreatic Cancer Research

ResearcherKanazawa UniversityNo recent work listed

Itasu Ninomiya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3356-5505; OpenAlex author ID A5048730959. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 12

  1. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined R… Co-author DOI 10.1097/mpa.0000000000001964↗
  2. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2020.2188↗
  3. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. Co-author DOI 10.21873/anticanres.13750↗
  4. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Co-author DOI 10.3892/mco.2018.1579↗
  5. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… Co-author PMID 30692318↗
  6. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Co-author DOI 10.3892/ol.2014.2553↗
  7. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2013.133↗
  8. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  9. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/etm.2012.482↗
  10. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Co-author DOI 10.3892/ol.2012.657↗
  11. Increased E-selectin in hepatic ischemia-reperfusion injury mediates liver metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2012.1896↗
  12. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic canc… Co-author DOI 10.3892/etm.2011.190↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tetsuo Ohta · 12 shared papers, 2011–2022 · strength 0.61
  2. Hidehiro Tajima · 12 shared papers, 2011–2022 · strength 0.61
  3. Isamu Makino · 11 shared papers, 2011–2022 · strength 0.57
  4. Mitsuyoshi Okazaki · 5 shared papers, 2018–2022 · strength 0.43
  5. Tomoharu Miyashita · 6 shared papers, 2013–2021 · strength 0.36
  6. S Kitamura · 2 shared papers, 2012 · strength 0.05
  7. Osamu Matsui · 2 shared papers, 2011–2013 · strength 0.04
  8. Toshifumi Gabata · 2 shared papers, 2011–2013 · strength 0.04
  9. Keisuke Yamazaki · 1 shared paper, 2014 · strength 0.04
  10. Yoshimichi Sai · 1 shared paper, 2013 · strength 0.03
  11. Koichi Tsuneyama · 1 shared paper, 2012 · strength 0.02
  12. K Yoshimoto · 1 shared paper, 2012 · strength 0.02
  13. Koïchi Shimizu · 1 shared paper, 2012 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.